French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change

Archive ouverte

Aquizerate, Aurélie | Laforgue, Edouard-Jules | Istvan, Marion | Rousselet, Morgane | Gerardin, Marie | Jouanjus, Emilie | Libert, Frédéric | Caous, Anne-Sylvie | Chaouachi, Leila | Chevallier, Cécile | Daveluy, Amélie | Eiden, Céline | Fauconneau, Bernard | Fournier-Choma, Christine | Gibaja, Valérie | Lacroix, Clémence | Lapeyre-Mestre, Maryse | Le Boisselier, Reynald | Revol, Bruno | Guerlais, Marylène | Victorri-Vigneau, Caroline

Edité par CCSD ; Oxford University Press (OUP): Policy B - Oxford Open Option D -

International audience. Background Since the appearance of zolpidem on the market, the occurrence of serious cases of abuse, misuse and dependence have come to the attention of authorities. In view of the increase in the number and severity of cases among zolpidem users and the predominant presence of zolpidem in falsified prescriptions, the French Health Authorities implemented part of the narcotics regulation for zolpidem in April 2017. The objective of this article was to describe the evolution of the abuse, dependence and misuse of zolpidem. Methods We used three data sources: (i) zolpidem is a reimbursable and strictly prescription drug in France. Medic’AM is a public database that indicates the number of tablets reimbursed each month in France for each reimbursable drug. This database has been analyzed as a proxy of the exposure of the French population to zolpidem; (ii) all French cases of drug dependence or abuse reported by health professionals (regulatory obligation) and (iii) an epidemiological tool based on the surveillance of falsified prescriptions over two periods: the 3-year period before the regulatory measure (2014–16) and the 3-year period after the regulatory measure (2018–20). Results This regulatory change had two immediate consequences: a sharp decline in falsified prescriptions and a decrease of ∼57% between the two study periods in the zolpidem reimbursement data. Markers of problematic consumption remained after the regulatory change with worsening cases, particularly for people who were genuinely dependent and/or had comorbidities or misusers for whom zolpidem was the substance of interest, whose proportion increased significantly in the addictovigilance notification system, from 43.6% (N = 107) to 59.3% (N = 127) (P < 0.01). Conclusions Further monitoring is needed in light of these persistent markers of problematic consumption.

Suggestions

Du même auteur

Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

Archive ouverte | Aquizerate, Aurélie | CCSD

International audience. Zopiclone, like zolpidem, is under surveillance in France due to its potential for dependence, abuse and misuse. However, part of the narcotics regulation was implemented in 2017 in France fo...

Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020

Archive ouverte | Diaz, Laurine | CCSD

International audience. ObjectivesAlprazolam, a high-potency and short-acting anxiolytic benzodiazepine, is one of the most misused benzodiazepines in France. In the context of various reports on alprazolam misuse d...

Trends in Fatal Poisoning Among Drug Users in France From 2011 to 2021

Archive ouverte | Revol, Bruno | CCSD

International audience. Importance The DRAMES (Décès en Relation avec l’Abus de Médicaments Et de Substances) register is a database of drug-related deaths with the aim of identifying the psychoactive substances ass...

Chargement des enrichissements...